ClinicalTrials.gg
RecruitingNCT06732193FPoCUpdated Sep 11, 2025

Fissios© and Postoperative Complications (FPoC Trial)

An interventional study of On-site respiratory physiotherapy and Fissios App in Surgical Procedure, Unspecified, Non Small Cell Lung Cancer and Surgery Scheduled, sponsored by Carlos Alfredo Fraile Olivero, MD, PhD.. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Carlos Alfredo Fraile Olivero, MD, PhD. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain — 160 open to participants now, 333 under way, 112 of them phase 3. Carcinoma, Non-Small-Cell Lung · Spain.

Planned enrollment
176th of 797
560 · median 188
Started
2025
with 58 others
No phase
12 of 851
7 open now
Primary completion
2026-12
later than 103 of 332 live
Registered
761st of 851
by date

Among the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, this one is the 176th largest by planned enrollment of the 797 interventional ones that give a count, is one of 59 that started in 2025, is one of 12 with no phase, reaches primary completion later than 103 of the 332 other live ones, and was the 761st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

160 of the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, or all of them as a file.
02

Study summary

Respiratory physiotherapy as part of a pre-operative physical training program may reduce the risk of developing post-operative complications, improving post-operative results and optimizing physical conditions in patients with a diagnosis of non-small cell lung cancer (NSCLC) undergoing lung resection surgery. During the post-operative period, performing physical exercise has also been proved to increase the capacity for exercise, improve health-related quality of life and reduce the feeling of breathlessness. Fissios App is a tool created by thoracic surgeons, physiotherapists and a specialist doctor in physical medicine and rehabilitation, which has been satisfactorily implemented in thoracic surgery patients; this contains a program of standardized respiratory physiotherapy exercises with a defined time and number of repetitions.

The aim is to compare the effectiveness of use of the Fissios App tool as a complement to a peri-operative respiratory physiotherapy program compared to just attendance at a face-to-face peri-operative respiratory physiotherapy program, to reduce the incidence of post-operative complications.

It is expected to include 560 patients in the study. Subsequent to evaluation by the investigator and the acceptance of participant to take part in the study, the performing of peri-operative respiratory physiotherapy is prescribed. The participants will be randomly assigned to a study group that uses the tool as a complement to the respiratory physiotherapy program or a control group that should only attend face-to-face respiratory physiotherapy sessions. All the participants should attend face-to-face respiratory physiotherapy classes taught by physiotherapists at the place and time set out in each centre before and after surgery for at least 45 minutes and at least five sessions. Moreover, study group participants may use the Fissios App tool. Investigators should fill in the pre-operative, surgery and post-operative data for each patient on the Fissios Research platform.

Read the detailed description

The FPoC Trial is designed as a multicentre, prospective, randomised, prospective, parallel, two-group, controlled, open-label, superiority study of only face-to-face respiratory physiotherapy or the use of Fissios App© as an adjunct to respiratory physiotherapy in patients scheduled for lung resection surgery.

The participants who take part in the study will be randomly assigned to the study or control group before the surgical procedure. All of them will follow an in-person respiratory physiotherapy programme, and the study group will complement this programme with the use of the Fissios App tool.

Perioperative care will be carried out in accordance with national and international guidelines. Postoperative complications will be recorded following the established definitions of the European Society of Thoracic Surgeons (ESTS) database and in the study protocol.

Finally, all the participants will be followed up for 90 days after the date of surgery to finalise the present study. The participants will continue the revisions following the protocols of each centre.

An estimated total of 560 particpants (280 per group) will be recruited for this study.

03

Conditions studied

  • Surgical Procedure, Unspecified
  • Non Small Cell Lung Cancer
  • Surgery Scheduled
  • Thoracic Surgery
  • Postoperative Complications
  • Perioperative Care

Keywords

  • Respiratory physiotherapy
  • Smartphone App
  • Post-operative complications
  • Peri-operative physical training
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients over 18 years of age.
  2. Indication for lung resection surgery due to diagnostic suspicion or histopathological diagnosis of non-small cell lung carcinoma.
  3. Anatomical lung resection surgery: anatomical segmental resection, lobectomies or pneumonectomies, using a conventional or minimally invasive approach (VATS, RATS).
  4. The patient has a smart mobile device compatible with the Fissios App©, has the ability or has the support to use it.
  5. Willingness and commitment to participate in the study.
  6. Ability to complete the to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Medical to perform respiratory physiotherapy exercises.
  2. Not possessing a smart mobile device compatible with Fissios App©.
  3. Inability of the patient to perform the exercises, either due to a physical or psychological impediment.
  4. Inability to complete the form for participation in the study.
  5. Refusal to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
560 participants (estimated)

Study arms

  • Active comparator
    In-person respiratory physiotherapy

    The patient must attend the respiratory physiotherapy sessions given by physiotherapists at the place and time established in each centre, before and after surgery.

    Procedure: On-site respiratory physiotherapy

  • Experimental
    Face-to-face respiratory physiotherapy plus use of the Fissios App

    The same protocol will be followed as for the control group and, in addition, the steps for downloading the application and the start-up will be explained verbally and in writing. The researcher will encourage the patient to use the Fissios App©, read all the perioperative medical recommendations and perform the respiratory physiotherapy exercises freely without restrictions in terms of time, time of use or location.

    Procedure: On-site respiratory physiotherapy · Device: Fissios App

Interventions

  • ProcedureOn-site respiratory physiotherapy

    The patient attends face-to-face physiotherapy sessions prescribed by the doctor.

  • DeviceFissios App

    The patient uses the Fissios App to perform respiratory physiotherapy exercises.

06

What researchers measure

Primary outcomes

  1. Postoperative complications

    Development of at least one adverse clinical event categorised as a postoperative complication during hospital admission. Immediately after the surgery until discharge.

    Time frame: Through postoperative evolution, an average of 2 weeks.

Secondary outcomes

  1. Duration of pleural drainage

    Time that the patient has pleural drainage from the end of surgery until medical discharge.

    Time frame: Through postoperative evolution, an average of 2 weeks.

  2. Mortality

    Patient status at the moment of discharge.

    Time frame: During hospitalization period, an average of 2 weeks.

  3. Hospital readmission

    Any clinical situation requiring hospital admission

    Time frame: Within 30 days of discharge from hospital

  4. Mortality

    Time frame: During the first 30 days after surgery

  5. Mortality

    Time frame: During the first 90 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Rami-Porta R, Wittekind C, Goldstraw P; International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005 Jul;49(1):25-33. doi: 10.1016/j.lungcan.2005.01.001. PubMed 15949587 ↗
  • Fernandez FG, Falcoz PE, Kozower BD, Salati M, Wright CD, Brunelli A. The Society of Thoracic Surgeons and the European Society of Thoracic Surgeons general thoracic surgery databases: joint standardization of variable definitions and terminology. Ann Thorac Surg. 2015 Jan;99(1):368-76. doi: 10.1016/j.athoracsur.2014.05.104. PubMed 25555970 ↗
  • Garutti I, Cabanero A, Vicente R, Sanchez D, Granell M, Fraile CA, Real Navacerrada M, Novoa N, Sanchez-Pedrosa G, Congregado M, Gomez A, Minana E, Pineiro P, Cruz P, de la Gala F, Quero F, Huerta LJ, Rodriguez M, Jimenez E, Puente-Maestu L, Aragon S, Osorio-Salazar E, Sitges M, Lopez Maldonado MD, Rios FT, Morales JE, Callejas R, Gonzalez-Bardancas S, Botella S, Cortes M, Yepes MJ, Iranzo R, Sayas J. Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program. Rev Esp Anestesiol Reanim (Engl Ed). 2022 Apr;69(4):208-241. doi: 10.1016/j.redare.2021.02.011. Epub 2022 May 15. PubMed 35585017 ↗
  • Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, Ljungqvist O, Petersen RH, Popescu WM, Slinger PD, Naidu B. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS(R)) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 2019 Jan 1;55(1):91-115. doi: 10.1093/ejcts/ezy301. PubMed 30304509 ↗
  • Fraile Olivero CA, Jarabo Sarceda JR, Fernandez Martin E, Santos Capa P, Arribas Manzanal PD, Gomez Martinez AM, Calatayud Gastardi J, Hernando Trancho F. Implementation of a perioperative care App in elective thoracic surgery. Cir Esp (Engl Ed). 2023 Apr;101(4):265-273. doi: 10.1016/j.cireng.2022.09.022. Epub 2022 Sep 12. PubMed 36108953 ↗
  • Rosero ID, Ramirez-Velez R, Lucia A, Martinez-Velilla N, Santos-Lozano A, Valenzuela PL, Morilla I, Izquierdo M. Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer. Cancers (Basel). 2019 Jul 5;11(7):944. doi: 10.3390/cancers11070944. PubMed 31284372 ↗
  • Mainini C, Rebelo PF, Bardelli R, Kopliku B, Tenconi S, Costi S, Tedeschi C, Fugazzaro S. Perioperative physical exercise interventions for patients undergoing lung cancer surgery: What is the evidence? SAGE Open Med. 2016 Oct 19;4:2050312116673855. doi: 10.1177/2050312116673855. eCollection 2016. PubMed 27803808 ↗
  • Mans CM, Reeve JC, Elkins MR. Postoperative outcomes following preoperative inspiratory muscle training in patients undergoing cardiothoracic or upper abdominal surgery: a systematic review and meta analysis. Clin Rehabil. 2015 May;29(5):426-38. doi: 10.1177/0269215514545350. Epub 2014 Aug 26. PubMed 25160007 ↗
  • Kendall F, Oliveira J, Peleteiro B, Pinho P, Bastos PT. Inspiratory muscle training is effective to reduce postoperative pulmonary complications and length of hospital stay: a systematic review and meta-analysis. Disabil Rehabil. 2018 Apr;40(8):864-882. doi: 10.1080/09638288.2016.1277396. Epub 2017 Jan 17. PubMed 28093920 ↗
  • Cavalheri V, Burtin C, Formico VR, Nonoyama ML, Jenkins S, Spruit MA, Hill K. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database Syst Rev. 2019 Jun 17;6(6):CD009955. doi: 10.1002/14651858.CD009955.pub3. PubMed 31204439 ↗
  • Sebio Garcia R, Yanez Brage MI, Gimenez Moolhuyzen E, Granger CL, Denehy L. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2016 Sep;23(3):486-97. doi: 10.1093/icvts/ivw152. Epub 2016 May 25. PubMed 27226400 ↗
  • Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev. 2017 Jun 7;6(6):CD012020. doi: 10.1002/14651858.CD012020.pub2. PubMed 28589547 ↗
  • Fraile Olivero CA, Sotillo Valenzuela L, Albarran Vidal V, Barcelo Cal JG, Alen Villamayor V, Hernando Trancho F, Fernandez Martin E, Calatayud Gastardi J, Gomez Martinez AM, Arribas Manzanal PD, Santos P, Fernandez Blanco R, Cal Vazquez MI, Milla Collado L, Rodriguez M, Perna V, Romero Roman A, Ordonez CA, Jarabo Sarceda JR. Fissios and postoperative complications (FPoC trial): a multicentre, randomised, controlled clinical trial. BMJ Open Respir Res. 2026 Jun 15;13(1):e003269. doi: 10.1136/bmjresp-2025-003269. PubMed 42303312 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 21 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Dec 13, 2024
StartActual
Mar 20, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732193
Lead sponsor
Carlos Alfredo Fraile Olivero, MD, PhD.
Collaborators
Spanish Society of Pneumology and Thoracic Surgery, Asociación Española de Afectados de Cáncer de Pulmón (AEACaP), Medtronic General Research Grant, Spanish Society of Thoracic Surgery (SECT)
Responsible party
Carlos Alfredo Fraile Olivero, MD, PhD. (Principal Investigator, Hospital San Carlos, Madrid) — Sponsor-investigator
First posted
Dec 13, 2024
Start date
Mar 20, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Carlos A Fraile Olivero, MD, PhD
Contact
carlosalfredo.fraile@salud.madrid.org
+34917043708
Lidia Sotillo, MD
Contact
lidia.sotillo@salud.madrid.org
+34917043717
Carlos A Fraile Olivero, MD, PhD
principal investigator · Hospital San Carlos, Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion